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1. Introduction 
In this chapter we consider the neuropsychopharmacology of ADHD in general and 
dopamine and the stimulants more specifically. Attention will be given to the various 
neurotransmitter theories for ADHD. We will consider the theoretical mechanisms of 
actions for the various medicines used to treat ADHD. We will look at how the stimulants, 
although often assumed to be similar, actually show evidence of differential mechanisms of 
action. We will look at new data that utilizes the technique of reverse microdialysis to 
demonstrate how different the dose-response curves are for dopamine release in the 
striatum following local application of the different stimulants.  
Throughout the text we will use ADHD (Attention-Deficit/Hyperactivity Disorder) without 
reference to the DSM-IV type, unless a specific reference pertains to combined, inattentive or 
hyperactive subtypes. 
2. Neuropsychopharmacology of stimulants 
The stimulant medications were discovered serendipitously with the indirect observation that 
amphetamines calmed and focused children who were given the medicine to try to treat 
headache that was caused by the technique of pneumoencephalography, a largely outdated 
procedure where the spinal fluid was drained and replaced with air in order to see the brain 
more clearly on X-ray (Bradley, 1937, Strohl, 2011). The form of amphetamine used by Bradley 
was Benzedrine, the racemic mixture, or 50/50 mixture of d- and l-amphetamine. Because of 
research pointing to the dopamine releasing qualities of the stimulants, the earliest theory for 
ADHD was that it represented a hypodopaminergic state. This hypodopaminergic state 
theoretically led to alterations in reward sensitivity if it was in the nucleus accumbens, 
hyperactivity if lowered dopamine was in the striatum, and decreased inhibitory control if the 
lowered dopamine was in the frontal cortex. Although the collective data never supported 
such clean demarcations in brain structure and dependence solely on dopamine, the 
“hypodopaminergic” theory of ADHD is still a popular teaching in the clinical setting. 
2.1 Dopamine and ADHD 
Dopamine was not always considered a neurotransmitter. As details about the 
neurotransmitters were emerging dopamine was noted as the penultimate molecule in the 
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synthesis of norepinephrine. The concept emerged of the monoamines being packaged into 
discrete vesicles that could be released when an action potential brought on an influx of 
calcium. Dopamine was transported into these synaptic vesicles by VMAT (Vesicular 
Monoamine Transporter). Then the enzyme Dopamine ┚-Hydroxylase inside the vesicle 
converted the dopamine to norepinephrine. Work by Carlsson and others in the 1950s 
showed that some regions of the brain, particularly the basal ganglia that includes the 
striatum and nucleus accumbens, were enriched in dopamine and had very little 
norepinephrine (Cooper et al., 2003). Following these discoveries, dopamine’s importance in 
coordinating motor control, Parkinson’s Disease, and reward were established. It was found 
that following release of dopamine from presynaptic vesicles that dopamine had specific 
receptors postsynaptically that could modulate the neurons function (both stimulatory and 
inhibitory modulation depending on the dopamine receptors and second messenger 
systems). Dopamine receptors were also found presynaptically and thought to allow for 
feedback mechanisms for precise regulation of dopamine release. Finally, dopamine’s effects 
were terminated both through reuptake into the presynaptic cytoplasm by the dopamine 
transporter (DAT), and by metabolism either inside the neuron by MAO (monoamine 
oxidase) or extracellularly by COMT (catechol O-methyl transferase) (see Figure 1).  
As discoveries about dopamine were evolving, stimulants were being used for many 
purposes in the mid to late 20th century. Bradley’s observations on amphetamine’s benefit 
for children with features of ADHD went largely ignored for several decades. The 
stimulants found use for their ability to keep people awake despite fatigue. Several 
militaries in World War Two used both amphetamine and methamphetamine for this 
purpose, although it was soon found that soldiers would “crash” following this use and 
need time to recover. Tolerance was also noted with increasing doses needed for effects such 
as euphoria. Abuse was reported for several decades before the FDA banned Benzedrine 
inhalers and limited amphetamines to prescription use only in 1959. Researchers in the 
1970s and 1980s connected and clarified the stimulants function in increasing dopamine in 
the synaptic cleft, as well as its connection to treating ADHD and the role of both tonic and 
phasic levels of dopamine (Robbins & Sahakian, 1979). Perhaps due to the ease of 
measurement and abudance of dopamine in the striatum and nucleus accumbens, dopamine 
research predominated over norepinephrine. In truth, amphetamines exert most of its CNS 
effects through dopamine and norephinephrine, with very little effects on serotonin. 
Methylphenidate is strongest at blocking dopamine and much less so norepinephrine, and 
even less so for serotonin (Gatley et al. 1996). Finally cocaine and methamphetamine seem to 
affect all three neurotransmitters, with their effect on serotonin theoretically leading to the 
greater euphoria. When this serotonin function is coupled to the reward function of 
dopamine release in the nucleus accumbens, it theoretically makes methamphetamine and 
cocaine have greater overall abuse potential compared to amphetamine and 
methylphenidate. To this day, stimulants are approved for use in ADHD, narcolepsy, and 
severe obesity; but with strict control by the FDA and other governmental agencies around 
the world. 
2.2 Other Neurotransmitters and ADHD 
As more intricacies have been revealed through animal models of ADHD and human 
research, other neurotransmitters have been implicated in ADHD. Perhaps the strongest 
case can be made for norepinephrine. Arnsten and colleagues have suggested that 
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norepinephrine is as important as dopamine in attention and ADHD. Recent elegant work 
in non-human primates suggest that alpha-2 adrenergic input in the frontal cortex is critical 
in maintaining working memory in a visual attention task constructed by Arnsten’s group 
(Wang et al., 2007). Interestingly, dopamine-1 receptor input is needed in the areas 
surrounding the circuitry of working memory to suppress areas of the frontal cortex that 
were not needed for that specific memory. One might say that norepinephrine was allowing 
for saliency and attention, and dopamine for signal-to-noise adjustment or inhibition of 
inappropriate information (Gamo et al., 2010).  
Initially one might think that atomoxetine lends credence to just the norepinephrine theories 
of ADHD in that it is a NET (norepinephrine transporter) inhibitor. But research has shown 
that the NET transports dopamine as well as NE. Thus atomoxetine raises NE and DA in the 
prefrontal cortex. Since NET is primarily present in the frontal cortex and not the nucleus 
accumbens or striatum, the neurotransmitter modulating effects of atomoxetine are only in 
the frontal cortex. This accounts for its lack of abusability, and perhaps the fact that 
atomoxetine overall is a less efficacious medicine for ADHD compared to amphetamine and 
methylphenidate (Lile et al., 2006). The stimulants in blocking DAT (dopamine transporter) 
also create increases in both DA and NE, since like NET, DAT transports both DA and NE. 
Other neurotransmitters implicated in ADHD include acetylcholine, histamine, adenosine 
receptors, and glutamate. Nicotinic receptors are involved in various tasks requiring 
attention and this has led to the speculation that the high rate of smoking seen in people 
with ADHD may be due in part to “self-medication”. Although most nicotinic medications 
have targeted Alzheimer’s, there use in memory may prove beneficial to ADHD. Several 
histamine-3-receptor antagonists are in the stages of being tested for ADHD and other 
cognitive disorder (Sander et al., 2008). Only a few studies have been reported thus far and 
their results using these histamine modulating drugs for ADHD have been mixed (Brioni et 
al., 2011). Caffeine, an adenosine receptor antagonist, can improve symptoms of ADHD in 
some animal models perhaps through interactions of adenosine receptors and dopamine 
systems. Caffeine is poorly studied in ADHD but appears to help alertness more than actual 
symptoms of ADHD (Smith 2002). Glutamate has recently been implicated from both 
neuroimaging and neuroscience. One open labeled trial has shown that glutamate 
modulating drugs, such as NMDA antagonist memantine shows some efficacy in treating 
ADHD (Findling et al., 2007). Interestingly a recent patch clamp study suggests that 
atomoxetine is also an NMDA antagonist at clinical levels (Ludolph et al., 2010). 
2.3 Heterogeneity amongst the stimulants 
Returning to the dopamine mechanisms of action involved in ADHD let us now focus on 
how the separate stimulants used in treating ADHD are different from each other. 
Methylphenidate has been shown to have a mechanism of action similar to cocaine in that it 
specifically blocks DAT (see Figure 1). D-amphetamine (the dextro-isomer of amphetamine) 
has been shown to have three potential mechanisms. The first is direct effect on the DAT by 
allowing reverse transport of DA from the cytoplasm presynaptically into the synapse, this 
is a calcium-independent DA release that is perhaps coupled to overall decrease in DA 
uptake. Secondly d-amphetamine inhibits MAO-B (Monoamine oxidase-B isoform) which 
catabolizes DA. Thirdly, d-amphetamine inhibits VMAT (vesicular monoamine transporter) 
leading to an increase in cytoplasmic DA that can be reverse transported out by DAT (see 
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Figure 1) (Bergman et al. 1989; Cadoni et al. 1995). Although it is not known which of these 
three mechanisms is the most important of note is that all three are different than 
methylphenidate. This agrees with the clinically observed phenomena that responses to 
methylphenidate and d-amphetamine are not always equal in patients. Thus, if a patient is 
not doing well on one stimulant, say methylphenidate, then it is the recommended standard 
of care to then try an amphetamine preparation. Sonders et al. (1997) categorized 
pharmacological agents that act on the human dopamine transporter (hDAT) into two 
groups: substrates for DAT (including dopamine and amphetamine) and cocaine-like 
(including cocaine and methylphenidate). Thus, amphetamine can actually serve as a 
substrate for DAT, like dopamine itself; whereas methylphenidate is not a substrate for 
DAT.  
 
Fig. 1. Simplified Model of Dopamine synapse with putative mechanisms of action for 
amphetamine and metylphenidate.  
But are all amphetamine preparations equivalent? What about the preparations such as 
Adderall that have some l-amphetamine (the opposite stereo isomer of d-amphetamine). In 
the 1990s the drug Adderall was introduced and marketed as a robust treatment for the 
symptoms of ADHD compared to other medications (Popper 1994; Patrick et al. 1997). One 
clinical study compared Adderall to D-amphetamine and found that Adderall decreased 
specific symptoms of hyperactivity slightly faster and over a longer time period than D-
amphetamine (James et al. 2001), but this was a minor difference. Other clinical trials 
support that Adderall is more effective than immediate-release methylphenidate on 
outcomes measured 4 to 5 hours after dosing (Pelham et al. 1999). A majority of data 
supports that population comparison of efficacy for stimulants in treating ADHD show little 
difference. It is only when you get to the individual patient that you find differences in the 
stimulants. For example, l-amphetamine alone has been tested and shown in a smaller study 
to be useful for some patients with ADHD, even a few which did not respond as well to d-
amphetamine (Segal 1974). More recent comparison of controlled-release preparations of 
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amphetamines and methylphenidate show little differences in overall efficacy. Previous in 
vivo voltammetry data in our laboratory showed differences in kinetics between 
amphetamine optical isomers (Glaser et al. 2005). In these studies, preparations with L-
amphetamine evoked faster DA rise times and signal decay times compared to D-
amphetamine. Additionally, data collected by our group showed greater amplitudes and 
longer DA response signal kinetics following local applications of Adderall in comparison 
with D-amphetamine and D,L-amphetamine (Joyce et al. 2007) supporting different 
mechanistic effects of these drugs on DA release.  
2.4 Reverse microdialysis of stimulants in the rat striatum: hypothesis 
When comparing different stimulant medications and their effects on dopamine levels, 
several caveats have limited direct comparison. First of all, stimulants are often given by 
intraperitoneal injection, due in part to its ease and the fact that the rapid rise in blood levels 
makes dopamine easier to measure in brain regions. However variability in absorption and 
first pass effects of the liver make it difficult to compare concentrations between 
medications. Gavage or oral delivery of food, while simulating the clinical experience for 
ADHD, has even more pharmacokinetic factors involved due to gut absorption factors as 
well. Finally, many injection and oral stimulant studies have to use larger, more abuse 
related dosing, because there are often little appreciable changes in dopamine at drug 
dosing similar to that used in ADHD, although a few studies have been able to accomplish 
this (Berridge et al, 2006). In order to circumvent some of these caveats, and yet still look at 
the in vivo effects of these drugs and their differences on striatum, we chose the technique of 
reverse microdialysis. This technology places the medication in the dialysate that goes 
directly to the striatum and allows for direct and sensitive dose-response curves for 
stimulant-evoked dopamine. 
The technique of reverse microdialysis coupled with high performance liquid 
chromatography with electrochemical detection (HPLC-EC) was used to study local drug-
evoked increases in extracellular dopamine (DA) levels and changes in DA metabolites in 
the striatum of anesthetized rats. Purdom et al. (2003) showed data supporting that the 
order of administration of different concentrations of D-amphetamine significantly affected 
DA and DOPAC levels. These results were likely attributable to changes in the surface 
expression of DAT on DA nerve endings and/or DAT function. Other in vitro studies have 
shown substrate dependent trafficking of the DAT to and from the plasma membrane and 
subsequent changes in the ability to transport DA (Kahlig et al. 2005; Johnson et al. 2005; 
Saunders et al. 2000; Kahlig et al. 2004; Kahlig and Galli 2003). Therefore to have the most 
accurate dose-response curves the same animal should not be used to test several doses. For 
these experiments drug-naïve animals were used to circumvent issues regarding DAT 
trafficking and/or change in function following substrate exposure (Kahlig and Galli 2003; 
Kahlig et al. 2004; Purdom et al. 2003). We tested the hypothesis that stimulant 
concentration-response curves of DA and its metabolites will display differential patterns of 
DA overflow that correlate with their mechanistic properties at the level of DAT function. In 
addition, we tested a unique formulation of 25% D- and 75%L-amphetamine and termed 
this mixture “Reverse Adderall”, to contrast it with Adderall that is ~75% D- and 25% L-
amphetamine. We hypothesized that the Reverse Adderall would also have a differential 
dose-response curve than the other amphetamine preparations. 
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2.5 Reverse microdialysis of stimulants in the rat striatum: methods 
Male Fischer 344 (F344) rats (3-6 months old) were anesthetized with urethane (1.25 g/kg 
i.p. in 0.9% saline). After placement into a stereotaxic frame (Kopf, Tujunga, CA, USA) with 
the incisor bar set at -2.3 mm, the rat striatum was prepared for study. Body temperature 
was maintained by use of an isothermal heating pad (Braintree Scientific, Braintree, MA, 
USA) at 37° C and periodically monitored by a rectal thermometer. After the retraction of 
the skin and tissue and exposure of the skull overlying the striatum, a small craniotomy (2 x 
2 mm) was carried out in the right hemisphere. The microdialysis probes were 
stereotactically placed with respect to bregma: +1.0 mm AP, ±2.2 mm ML, DV -6.0 mm) 
(Paxinos and Watson, 1986). The 2-mm length membrane probes (CMA/11, CMA 
Microdialysis, Stockholm, Sweden) remained at this location for the duration of the 
experiment. All procedures were performed in accordance with the National Institutes of 
Health Guidelines for the Care and use of Mammals in Neuroscience and Behavioral 
Research (2003) and were approved by the Animal Care and Use Committee of the 
University of Kentucky. 
Fluid flow through the microdialysis probes was achieved using a syringe pump (KDS230, 
KD Scientific, Holliston, MA) fitted with 1ml gastight syringes (1001 LTN, Hamilton USA, 
Reno, NV) containing dialyzing fluid. Dialysis probes were perfused at a flow rate of 1 
µl/min. Syringes were connected to a liquid switch (CMA/110, CMA Microdialysis, 
Stockholm, Sweden) that allowed for alternation between treatments: artificial cerebral 
spinal fluid (aCSF) (in mM: NaCl 123, KCl 3, CaCl2 1, MgCl2 1, NaHCO3 25, NaH2PO4 1, 
and glucose 5.9) and aCSF + [drug]. Teflon tubing (FEP tubing, 0.12 mm i.d.) and tubing 
adapters (CMA Microdialysis, Stockholm, Sweden) were used to establish all connections. 
Samples were collected at twenty minute intervals into a 0.2 ml microcentrifuge tube and 
manually injected into an HPLC-EC system. The order of administration for each of the 
drug solutions tested was as follows: samples 1-6 (0-120 minutes, aCSF), sample 7 (120-140 
minutes, aCSF + stimulant drug solution), samples 8-12 (160-240 minutes, aCSF).  
Probe recoveries were collected using a standard solution with known concentrations of 
DA, norepinephrine (NE), serotonin (5-HT), 3,4-dihydroxphenylacetic acid (DOPAC), 
homovanillic Acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA). In order for a probe to 
be used in these studies, in vitro recoveries of 10% ± 1 were required. Based on this 
exchange rate, seen for molecules similar in size to amphetamine such as DA, NE, and 5-HT, 
we were able to more accurately adjust the effective concentrations of stimulant drugs being 
studied.  
Stimulant concentrations used for reverse microdialysis studies were chosen to represent a 
range that included clinically relevant levels and abuse levels that were normalized for the 
amount of D-amphetamine. Our prior studies support that D-amphetamine determines the 
amount of DA released in the presence of both enantiomers (Glaser et al. 2005). The 
following concentrations were used based on ~10% exchange rate for the microdialysis 
probes: for D-amphetamine and methylphenidate, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 25 
µM, 50 µM, 100 µM, 400 µM were studied; for Reverse Adderall, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 
10 µM, 25 µM, 50 µM, 100 µM, 400 µM and 533 µM; ; and for Adderall , 0.1 µM, 0.5 µM, 1 
µM, 5 µM, 10 µM, 25 µM, 50 µM, 100 µM, 400 µM and 539 µM solutions were studied . For 
D,L-amphetamine (normalized to D-amphetamine/2), L-amphetamine, and cocaine, only a 
concentration of 400 µM was tested for maximum effect comparisons. Prior to each 
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experiment, 20 mM ascorbic acid was added to each solution and solutions were aerated 
with 95% O2/5% CO2. Solutions were immediately added to individual 1 ml gastight 
syringes. Following each experiment, rats were intracardially perfused with 0.9% NaCl 
solution followed by a 4% paraformaldehyde solution. They were then decapitated, and 
their brains were frozen, sliced on a cryostat, and sectioned stained with cresyl violet to 
verify probe placement in the striatum.  
High-Performance Liquid Chromatography Coupled with Electrochemical Detection 
(HPLC-EC) analysis followed the methods previously described by Hall et al. (1989). The 
low level detections of DOPAC, DA, 5-HT, NE, 5-HIAA, and HVA were performed using an 
isocratic HPLC system (Beckman, Inc., Fullerton, CA) coupled to a dual-channel 
electrochemical array detector (model 5300A, ESA, Inc., Chelmsford, MA), E1 = +0.35 mV 
and E2 = -0.25 mV, with an ESA model 5011A dual analytical cell. The compounds of 
interest were separated with reverse-phase chromatography, using a C18 column (4.6 mm x 
75 mm, 3 µm particle size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan) 
with a pH 4.1 citrate-acetate mobile phase, containing 4% methanol and 0.34 mM 1-octane-
sulfonic acid delivered at a flow rate of 2.0 ml/min. Peaks for the analytes were identified 
by retention times from known standards.  
Data were collected from 5-6 animals per 10 drug concentrations (for Adderall, D-
amphetamine, Reverse Adderall, and methylphenidate). Data were collected for 5-6 animals 
for the highest drug concentration only for L-amphetamine, D,L-amphetamine, and cocaine. 
The raw microdialysis values were expressed as nM based on a 1 x 10-7 M mixed standard 
of known analytes and probe recoveries of ~ 10%. Outliers were excluded based on data 
falling outside of 2 standard deviations from the mean. Concentration-response curves were 
constructed based on the mean peak DA overflow concentration following the twenty 
minute reverse microdialysis of each drug concentration. GraphPad Prism statistical 
analysis software, version 4.0 (Prism, San Diego, CA, USA), was used to determine the 
appropriate nonlinear curve fit and Log half maximal effective concentration (EC50) of each 
drug. An initial one-way analysis of variance was used to determine significance of DA 
overflow from the aCSF control. A second one-way analysis of variance was used followed 
by post-hoc t-tests with Bonferroni’s corrections to compare DA release produced following 
reverse microdialysis of clinically relevant drug concentrations and maximum 
concentrations. Potency measures were defined by the stimulant that reached its half-
maximal response on the concentration-response curve with the lowest effective 
concentration of stimulant. Efficacy measures were defined by the highest amount of DA 
overflow evoked when all stimulant concentrations were at maximal levels. Statistical 
significance was defined as p<0.05. 
2.6 Reverse microdialysis of stimulants in the rat striatum: results 
Average baseline levels of DA (<10 nM) were measured and found to be similar to 
previously collected data in the striatum of anesthetized and awake-behaving rats (Gerhardt 
and Maloney 1999; Ferguson et al. 2003; Garris et al. 1994; Kawagoe et al. 1992; Parsons and 
Justice 1992). Baseline DOPAC levels were determined to be (~800-1000 nM) in the rats used 
for the D-amphetamine and Adderall studies and are similar to previously reported levels 
(Ferguson et al. 2003). The DOPAC data are reported as percent of baseline due to increased 
variance in baseline samples collected from the rats used for the Reverse Adderall and 
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methylphenidate studies (Fig. 3). Levels of the DA metabolite homovanillic acid (HVA), 5-
hydroxyindoleacetic acid (5-HIAA) and serotonin (5-HT) levels were measured and 
concentration-dependent effects were not detected (data not shown).  
The twenty minute local tissue perfusions of drugs induced a concentration-dependent 
increase in DA overflow followed by a 60 minute time period to return to baseline 
supporting the DAT and DA uptake blocking effects of the tested stimulants (Wise and 
Hoffman 1992; Sulzer et al. 1993; Schweri et al. 1985). The resulting DA levels, at the highest 
concentration of drug, were similar to previous microdialysis measures of ~150 nM (Seeman 
and Madras 2002). The measures of DA were seen to decline over 2 more fractions post drug 
administration. Furthermore, applications of the lowest stimulant concentration resulted in 
DA levels that were not statistically different from those seen after reverse microdialysis of 
the artificial cerebral spinal fluid (aCSF) control. 
The resulting D-amphetamine concentration-response curve for extracellular DA in rat 
striatum displayed an unexpected double-sigmoidal pattern with two plateaus. Plateaus in 
the amount of DA overflow occurred at the lower concentration (1 µM D-amphetamine) and 
at a higher concentration (100 µM D-amphetamine). At 0.1 µM D-amphetamine, little or no  
 
Fig. 2. Dose-Response curves for evoked overflow of dopamine in the rat striatum by 
various stimulants. 
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increase in DA overflow resulted in comparison to aCSF control; and no significant 
differences were found between 100 µM and 400 µM D-amphetamine supporting an upper 
plateau in DA measures (Figure 2). Two half-maximal effective concentration (EC50) values 
are indicated for the higher potency (lower plateau) and lower potency (upper plateau) 
portions of this concentration-response curve (Table 1).  
 
Drug 
EC50 [Drug] (M) 
For DA 
Maximum Response 
(µM) For DA 
Methylphenidate 10 138.7±22.2 
Adderall 25 184.6±12.3 
D-amphetamine II 50 144.5±15.6 
Reverse Adderall 50 176.7±19.1 
D-amphetamine I 0.5 N/A 
Table 1. Stimulant Potency and Efficacy on DA Measures 
 
 
Fig. 3. Dose-Response curves for overflow of dopamine metabolite DOPAC in the rat 
striatum by various stimulants. 
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The methylphenidate concentration-response curve for extracellular DA in the rat striatum 
also supports a concentration-dependent increase in DA levels (Figure 2). Since 
methylphenidate had previously been characterized as a DAT blocker and not a substrate 
that undergoes transport through the DAT, we hypothesized that we would see much lower 
levels of DA release in an anesthetized rat. It was therefore surprising to see that 
applications of 0.5-400 µM methylphenidate increased DA concentrations significantly 
greater than aCSF control. However, in contrast to d-amphetamine, 0.1 µM methylphenidate 
did not cause increased DA release that was significantly different from control. The two 
highest concentrations tested (100 and 400 µM) were not significantly different in the 
amount of DA release (Figure 2).  
The Adderall concentration-response curve for extracellular DA measured in the rat 
striatum demonstrated a similar range of evoked DA overflow, although the dose-response 
curve was closer to a single sigmoidal curve (Figure 2). An upper plateau in DA levels 
occurred at 100 µM Adderall, as 100 µM and 400 µM Adderall were not significantly 
different in response. At 0.1 µM, Adderall did not produce DA levels that were significantly 
different from local application of aCSF control.  
Finally, the Reverse Adderall (75% L-amphetamine, 25% D-amphetamine) concentration-
response curve for extracellular DA showed a concentration-dependent increase in evoked DA 
at all concentrations tested except for 0.1 µM; which was not significantly different from aCSF 
control (Figure 2). While Reverse Adderall was predominantly made of L-amphetamine, it did 
not increase DA levels to the extent of Adderall at some concentrations (Table 1). The highest 
two concentrations of Reverse Adderall tested were significantly different supporting that a 
plateau of DA measures will likely occur at a higher concentration. 
Figure 3 shows the individual tracings of detected DOPAC levels (represented as % of 
baseline) following reverse microdialysis of D-amphetamine at multiple concentrations. D-
amphetamine, Adderall, and Reverse Adderall inhibited DOPAC levels in a similar manner 
following local perfusion of drug at 120 minutes and continued to decrease DOPAC 
production up to one hour when DOPAC levels returned to baseline. While methylphenidate 
caused increased DA levels similar to the other stimulants, it did not affect DOPAC levels in a 
consistent manner and was similar in this aspect to the effects of cocaine.  DOPAC production 
was less affected by methylphenidate and cocaine in comparison to Adderall (p<0.001), and D-
amphetamine (p<0.01, p<0.05). Reverse Adderall, L-amphetamine, and D,L-amphetamine all 
caused significantly greater effects on DOPAC levels in comparison to cocaine (p<0.001). An 
initial increase in DOPAC was seen following application of 100 µM and 400 µM 
methylphenidate followed by a decrease similar to that of other concentrations without a 
pronounced concentration-dependent pattern (data not shown).  
2.7 Reverse microdialysis of stimulants in the rat striatum: implications 
These data represent novel findings regarding the effects of various stimulants across a 
range of concentrations on dopamine release in the striatum. The concentration-response 
curve for D-amphetamine displayed a double-sigmoidal pattern that supported dual-
functionality properties of the DAT and/or differential mechanisms by which high and low 
levels of D-amphetamine affect DA efflux. In addition, these data show for the first time that 
local applications of methylphenidate increased DA levels in a concentration-dependent 
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pattern and even demonstrated a greater EC50 (DA) when compared to other stimulants. 
These data are in agreement with our previous in vivo high speed chronoamperometric data 
that support the robust local activity of Adderall compared to other ADHD medications 
(Joyce et al. 2007). Decreased DA levels caused by cocaine compared to higher DA levels 
after local application of methylphenidate suggest dissociation between the local effects of 
methylphenidate and cocaine. DOPAC levels in these studies showed significant decreases 
following additions of any of the amphetamine preparations in a dose- dependent fashion, 
whereas cocaine and methylphenidate were less effective in inhibiting DOPAC production. 
The data shown here are consistent with the known DA releasing properties of 
amphetamine predominantly due to DAT reversal of normal reuptake into the presynaptic 
terminal (Giros et al. 1996). Likewise, amphetamine has been shown to impair DA reuptake, 
inhibit MAO activity, and affect vesicular conditions that lead to emptying of vesicular 
stores via the vesicular monoamine transporter 2 (VMAT2) (Horn et al. 1971; Sulzer et al. 
1995; Dubocovich et al. 1985; Heikkila et al. 1975; Uretsky and Snodgrass 1977; Green and El 
Hait 1978; Cadoni et al 1995). Our previous data support amphetamine enantiomeric 
differences that could not be accounted for across multiple concentrations due to technical 
limitations; particularly with the current difficulties of studying the effects of low levels of 
these drugs on DA release using in vivo electrochemical methods (Glaser et al., 2005). We 
chose to carry out these studies in this manner based on information supporting the 
dynamic changes that occur in DA neuronal systems in response to DAT substrates and 
inhibitors. Purdom et al. (2003) showed data supporting that the order of administration of 
different concentrations of D-amphetamine significantly affected DA and DOPAC levels. 
These results were likely attributable to changes in the surface expression of DAT on DA 
nerve endings and/or DAT function. Other in vitro studies have shown substrate 
dependent trafficking of the DAT to and from the plasma membrane and subsequent 
changes in the ability to transport DA (Kahlig et al. 2005; Johnson et al. 2005; Saunders et al. 
2000; Kahlig et al. 2004; Kahlig and Galli 2003). Therefore we used stimulant-naïve animals 
for these studies, an important but often neglected consideration in many mechanistic 
studies of stimulant medications. 
While we have described the use of voltammetric studies to investigate the properties of 
stimulants at low levels, it is difficult to accurately predict what the resulting effective 
concentrations were in these studies. Voltammetry affords the ability to study 
neurotransmission with high temporal and spatial resolution; however, we lose a 
magnitude of sensitivity that is available using microdialysis coupled with HPLC-EC. Using 
HPLC-EC to analyze samples collected during reverse microdialysis (local application) of 
stimulant drugs allows for studies to be carried out with lower drug concentrations. These 
studies were designed to complement our previous studies and mimic longer 
administration (over 20 minutes) in converse to the rapid pressure ejection used earlier (20 
seconds). As a final rationale of this work, we proposed to investigate complete 
concentration-response studies using reverse microdialysis coupled with HPLC-EC. 
Investigations of concentration-response patterns were intended to increase our 
understanding of ADHD drug mechanistic activity by looking at their effects on DA and 
metabolite levels.  
Although we did measure norepinephrine (NE) with our HPLC methods, the peak was not 
consistently measurable due to its proximity to the solvent edge. In addition, NE is not a 
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common neurotransmitter in the striatum. Therefore, one caveat of our study is that it does 
not investigate the possibility that NE elevation, and not DA, in the PFC (and not the 
striatum) is most important for clinical efficacy in ADHD. This theory goes on further to 
state that DA is elevated in the synapse only at higher doses of stimulants and that this leads 
more to the rewarding symptoms and drug-abuse potential (the downward slope of the 
theoretical inverted-U of stimulant action). Our data would suggest that this may be true for 
methylphenidate, but that d-amphetamine does involve appreciable DA at lower-doses that 
may work in concert with NE in the PFC. This would also give credence to the fact that the 
two main stimulants are both tried on patients with ADHD because some will respond well 
to one and not the other, where as other patients respond to both. Obviously, a repeat of this 
study using microdialysis in the PFC and an HPLC method to pick up the lower levels of 
DA and NE in the PFC would be needed to answer this mechanism of action question. 
One possible mechanism for the D-amphetamine double-sigmoidal concentration-response 
curve involves targeting of specific DA pools and amphetamine concentration-dependent 
effects. Some data support contribution of both cytosolic and vesicular stores to the released 
DA following exposure to amphetamine (Pifl et al. 1995); while other data indicate a 
predominant vesicular DA contribution (Jones et al. 1998). Jones et al. (1998) measured DA 
released following electrical stimulation and amphetamine perfusion of striatal brain slices 
and noticed a delay in DA release with amphetamine, supporting that DA had to be 
redistributed to the cytosol prior to being released from the cell. Based on these different 
contributions to amphetamine-evoked DA increases, we suggest that lower concentrations 
of D-amphetamine release “newly synthesized” DA pools in the cytosol, and higher 
concentrations contribute to the emptying of vesicular stores. Together this produces a 
biphasic pattern and a marked increase in the amount of DA released at the higher 
concentrations (Seiden et al. 1993; Langeloh and Trendelenburg 1987; Sulzer et al. 
1993,2005).  
An alternative mechanism for the D-amphetamine concentration-response curve might be 
explained by an upregulation of DAT levels caused by stimulation of D2R autoreceptors 
leading to second messenger regulation. Others have reported a link between stimulation of 
D2R autoreceptors and levels of membrane DATs (Parsons et al. 1993; Cass and Gerhardt 
1994; Rothblat and Schneider 1997; Dickinson et al. 1999; Hoffman et al. 1999; Mayfield and 
Zahniser 2001). For example, decreased DA clearance in the striatum, prefrontal cortex, and 
nucleus accumbens after administration of the D2R agonist raclopride has been 
demonstrated (Cass and Gerhardt 1994). In addition, acute amphetamine stimulation caused 
increased synaptosomal DAT surface expression that occurred within 30 seconds (Johnson 
et al. 2005) indicating the rapid trafficking of the DAT and supporting that these changes 
would have occurred during the time frame we were sampling (Saunders et al. 2000). Due to 
the comparatively increased sensitivity of D2R autoreceptors, low levels of extracellular DA 
are sufficient to stimulate these autoreceptors that would result in increased DA clearance 
(Cooper et al. 2003) (Fig. 4). The small amounts of released DA required to stimulate these 
autoreceptors would be taken up quickly through increased levels of membrane DATs, 
supporting the effects we see with the first plateau of the D-amphetamine concentration-
response curve. At higher concentrations of D-amphetamine, increased DA clearance will 
likely be followed by autoreceptor desensitization caused by the high levels of DA released 
after such a robust concentration of drug (Khoshbouei et al. 2004; Gorentla and Vaughan 
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Fig. 4. Theoretical model of activity describing the double Plateaus of the D-amphetamine 
concentration-response curve for DA: Plateau I Low [D-amphetamine]: Lower 
concentrations of D-amphetamine cause reverse transport of low levels of DA through the 
DAT. In addition, DA sensitive D2R autoreceptors are stimulated. Due to the increased 
clearance of DA, the result is the first plateau of the concentration-response curve. Plateau 
II High [D-amphetamine]: Amphetamine has been shown to interact with DATs and 
facilitate DA release followed by DAT internalization. Higher concentrations of D-
amphetamine will likely cause increased DA release and DAT internalization. D2R 
autoreceptor desensitization is likely to occur and interrupt DAT expression. Higher 
levels of extracellular DA and decreased DA clearance likely cause the second plateau. 
2005; Kim et al. 2001; Namkung and Sibley 2004; Ferguson et al. 1996; Tang et al. 1994) (Fig. 
4). Finally, data support that interactions of amphetamine and the DAT lead to DAT 
internalization via phosphorylation of target residues in the C- and N- termini (Khoshbouei 
et al. 2004; Kahlig et al. 2006; Fog et al. 2006), that may contribute to the effects we see in the 
second plateau of the D-amphetamine concentration-response curve. We propose that the 
amount of D-amphetamine in Adderall leads to a similar but slightly different 
concentration-response curve. Previous in vivo electrochemical data support the faster 
kinetics of the effects of L-amphetamine in combination with the slower kinetics of D-
amphetamine could allosterically modulate DAT trafficking rendering a concentration-
response with less apparent plateaus (Glaser et al. 2005; Joyce et al. 2007). Another possible 
correlation is the similar EC50 for both the second D-amphetamine sigmoidal curve and the 
DOPAC decrease consistent with MAO inhibition. 
While the double plateaus we note here are in regards to increasing concentrations of D-
amphetamine, other reports suggest biphasic effects of catecholamine transporters over 
different parameters. Johnson et al. (2005) described the effects of amphetamine on DAT 
surface expression in rat synaptosomes. They described initial amphetamine upregulation of 
DATs to the plasma membrane leading to DA efflux followed by amphetamine induced 
internalization of DATs after repeated doses of amphetamine. Jayanthi et al. (2005) described 
mechanisms that contribute to a biphasic regulation of endogenous serotonin transporters 
(SERTs) expressed in platelets. Protein Kinase C (PKC) activation in platelets resulted in the 
initial reduction of functional SERTs followed by enhanced endocytosis of SERTs.  
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Intraperitoneal administration of methylphenidate in freely-moving rat has been shown to 
cause increases in DA levels measured in dialysates and some argue that the greatest effects 
were seen in the prefrontal cortex (Hurd and Ungerstedt 1989; Berridge et al. 2006). In 
particular, Hurd and Ungerstedt found that amphetamine and methylphenidate caused 
similar increases in DA levels; however, methylphenidate caused these levels over a longer 
time period correlating with the robust effects of methylphenidate we present here. This 
study also reported that methylphenidate had less of an effect on decreasing DOPAC levels 
compared to the more pronounced decrease caused by amphetamine (Hurd and Ungerstedt 
1989). In terms of behavioral effects, D-amphetamine and methylphenidate have been shown 
to induce locomotor activity at low doses and cause stereotypies at higher doses (Fessler et al. 
1980; Hughes and Greig 1976; Scheel-Kruger 1971). Additionally, methylphenidate has also 
been found to be reinforcing in regards to drug abuse potential in humans, and it has been 
self-administered in animal models (Stoops et al. 2005; Rush et al. 2001; Risner and Jones 1975). 
In general, cocaine and methylphenidate are thought to work in a similar manner by 
predominantly acting as competitive inhibitors of the DAT (Wu et al. 2001) and increases in 
extracellular DA result predominantly from this blockade after impulse-dependent release 
of DA. However, the robust extracellular effects of methylphenidate in this study argue 
against this concept as the effects observed mirror d-amphetamine and not cocaine. 
While the argument can be made that the studies herein that involve local applications of 
drugs fail to account for pharmacokinetic differences between these stimulants, we propose 
that this is a particular strength of our study. For these experiments, drugs were applied 
over a range of levels, including clinically relevant concentrations (10-50 µM) and 
potentially drug abuse levels (>400 µM) (West et al. 1999; Shader et al. 1999; Kuczenski and 
Segal 2001; Solanto et al. 2001; Grilly and Loveland 2001). The low concentrations were 
projected to simulate potential levels of drug that would be present in brain tissue following 
systemic or oral administration. Finally, administering the drugs via reverse microdialysis 
eliminated pharmacokinetic issues from the study allowing for more of the pure effects of 
the drugs on DA nerve terminals.   
In summary, we have shown that the D-amphetamine concentration-response curve of DA 
displayed a double plateau pattern indicating effects on DA stores and/or rapid regulation 
of DAT trafficking and/or function. These data support that methylphenidate may cause 
DA release in addition to acting as a DA uptake inhibitor. Taken together, these data explain 
the effects of clinically available stimulants on DA levels over a range of concentrations and 
confirm that methylphenidate, d-amphetamine, and combinations of amphetamine isomers 
have potent, yet different, effects on dopamine in the striatum. 
2.8 Future directions in the neuropsychopharmacology of ADHD 
The data presented herein demonstrates the translational aspect of how the currently 
available stimulants are different from each other, and therefore backs up the current 
practice of trying different stimulants on patients to maximize efficacy and minimize side 
effects. It is also suggests that other percentages of l-amphetamine may be useful to test in 
the future for some patients with ADHD may respond better to them. Yet, this data does 
little to address some of the larger problems that face us in understanding ADHD and in 
finding superior treatments for ADHD. Some might argue that the stimulants are largely 
effective and safe already. But with the risk of abuse and diversion, the fact that many 
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adolescents and adults do not like how they feel on them and many other factors such as 
whether or not they truly decrease a person’s subsequent risk for substance abuse, there is still 
room for improved medications. Perhaps one goal may be to find a medication that truly helps 
only those with ADHD, since stimulants actually can be “performance enhancing” drugs that 
can give people such as college students without ADHD benefits in studying or taking tests 
with little knowledge of their possible dangers or ethical implications. 
In the future it will be useful to more fully understand not only the neurotransmitters involved 
in the various aspects of ADHD, but the way that circuitry and brain region interact to lead to 
dysfunction. Neuroimaging may contribute greatly to this as it obtains greater resolution and 
ways to measure separate neurotransmitter systems. Our lab and others have begun to use 
neurotransmitter specific probes to measure more accurately second by second changes in 
neurotransmitters. We are finding the milieu is much more heterogeneous than previously 
understandable by microdialysis. As microelectrode technology improves and gets more 
compact, real-time recordings of multiple brain areas while the animal is awake will answer 
more questions and allow for more precise drug development. Finally, pharmacogenomics is 
starting to yield some benefit and may help in more targeted use of the right stimulants for the 
right patient instead of the trial and error method now employed.  
3. Conclusion 
In this chapter we have reviewed the case for dopamine’s role in ADHD especially as it 
pertains to the mechanisms of action of the stimulants methylphenidate and the various 
amphetamines. We have also shown how many other neurotransmitters are involved in 
ADHD and alternative medications for ADHD. No doubt as the neuropsychopharmacology 
of ADHD evolves, we will discover more intricate details about the relative contributions of 
the neurotransmitters and how they relate to the genetic and neurocircuitry levels of our 
understanding. The ultimate goal of this knowledge is to improve treatment and maximize 
safety for people of all ages with ADHD. 
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